Approval Alert | Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma

In October 2022, the FDA approved tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma.

Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Video
Ghassan K. Abou-Alfa, MD, Discusses Next Steps in Researching Unresectable HCC
Nov 23, 2022 9:00 PM
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Video
Ghassan K. Abou-Alfa, MD, Spotlights Patients With Unresectable HCC Who May Best Benefit From Tremelimumab/Durvalumab
Nov 12, 2022 3:00 PM
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Video
Ghassan K. Abou-Alfa, MD, Discusses Importance of Treatment Accessibility in Unresectable HCC
Nov 6, 2022 5:00 PM
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Video
Ghassan K. Abou-Alfa, MD, Highlights Approval of Tremelimumab and Durvalumab in Unresectable HCC
Oct 31, 2022 8:00 PM
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
FDA Approves Tremelimumab Plus Durvalumab in Unresectable HCC
Article
FDA Approves Tremelimumab Plus Durvalumab in Unresectable HCC
Oct 24, 2022 3:02 PM
Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.